📈 Jumpstart Signal Watchlist — October 06, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $14.36 is 3% below 3yr high $14.81 · ⏳ SMA200 $7.42 (current price $14.36 is above) · 💰 Market Cap $811M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.1%)
- 🔔 Strong above EMA50 (17.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×2).
✅ Paysign (NASDAQ:PAYS) Sets New 1-Year High — MarketBeat.
🤖 The article reports Paysign shares reached a new 52-week high and notes the company beat quarterly earnings and revenue expectations. It also cites analyst price-target increases and a broadly positive consensus rating.
✅ DA Davidson raises Paysign stock price target to $15 on growth outlook — Investing.com.
🤖 DA Davidson raised its price target from $12 to $15 while maintaining a Buy rating. The article also notes Paysign beat second-quarter expectations and raised its full-year outlook.
⚪️ Paysign EVP, operations Joan Herman sells $716,899 in shares — Investing.com.
🤖 The article reports an executive's share sales, which were made under a previously adopted Rule 10b5-1 trading plan. It also mentions the company's recent earnings beat and raised outlook, but the reported transactions themselves are not a directional catalyst.
⚪️ Paysign chief innovation officer Michael Ngo sells $1.9m in stock — Investing.com.
🤖 The article reports the chief innovation officer sold shares. It also references Paysign's earnings beat and raised outlook, but the share-sale disclosure itself is not a directional catalyst.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.60 is 8% below 3yr high $12.66 · ⏳ SMA200 $9.02 (current price $11.60 is above) · 💰 Market Cap $2.0B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (5.7%)
- 🔔 Strong above EMA50 (10.4%)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×1; showing 3 of 4).
✅ Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 — Yahoo Finance.
🤖 Vir announced it will present expanded Phase 2 SOLSTICE data on its hepatitis delta combination at an upcoming medical meeting. The planned data presentation is a potential catalyst for the company’s clinical program.
✅ Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data — Investing.com.
🤖 Raymond James maintained its Strong Buy rating and $19 price target after a competitor’s Phase 3 results, saying those results did not change its view of Vir’s pivotal studies. The reaffirmation supports a positive analyst outlook for VIR.
⚪️ Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer — Business Wire.
🤖 Vir appointed Aziz Sawaf as executive vice president and CFO, effective October 5. The leadership change is company-specific but the announcement provides no financial or clinical update indicating a clear stock-price direction.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $78.02 is 3% below 3yr high $80.25 · ⏳ SMA200 $54.96 (current price $78.02 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ Red Violet (NASDAQ:RDVT) Reaches New 12-Month High — MarketBeat.
🤖 Zacks Research upgraded Red Violet from Hold to Strong Buy, and the article notes a consensus Buy rating with an $83.50 average price target. It also mentions Raymond James’ Outperform rating and $90 target.
✅ Red Violet (RDVT) Expands FOREWARN Reach Through Partnership With Pacific West Association of REALTORS — Yahoo Finance.
🤖 FOREWARN’s collaboration with the Pacific West Association of REALTORS will make its identity-verification and safety solutions available to more than 10,000 members. The partnership expands the platform’s reach, though the article does not quantify its financial impact.
⚪️ Red Violet (NASDAQ:RDVT) Reaches New 1-Year High — MarketBeat.
🤖 The article reports that Red Violet shares reached a new 52-week high, a price milestone rather than a company-specific business catalyst. It also recaps analyst ratings and earlier quarterly results.
⚪️ Red Violet, Inc. (NASDAQ:RDVT) Stock Rated "Buy" by Wall Street Analysts — MarketBeat.
🤖 The article reports a consensus Buy rating and an average price target of $83.50, while also noting a recent downgrade to Hold. It summarizes analyst opinions rather than announcing a new company operating development.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Magnite is an advertising technology company that provides a sell-side platform for digital advertising. Its software helps publishers and media owners manage and monetize ad inventory across channels like connected TV, video, mobile, and desktop, while also connecting them with advertisers and agencies.
- 🎯 Current $24.84 is 6% below 3yr high $26.52 · ⏳ SMA200 $17.01 (current price $24.84 is above) · 💰 Market Cap $3.6B
- MGNI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 62% (>20%); ROE 18% (>15%); Low LT D/E 0.37 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Magnite Gets Price Target Boost As Google Ad-Tech Ruling Could Lift Its Market Share — Yahoo Finance.
🤖 BofA raised its price target to $38 from $25 and maintained a Buy rating, citing potential for Magnite to gain open-web advertising share following changes ordered in Google's ad-tech practices. The expected market-share gains are prospective, so the catalyst carries some uncertainty.
✅ Magnite Named Primary Video Ad Server and a Programmatic Technology Provider for HP TV+ — GlobeNewswire.
🤖 HP TV+ selected Magnite as its primary video ad server and programmatic technology provider, adding a new streaming platform to Magnite's customer base. The deal also uses Magnite's SpringServe, programmatic activation, and ClearLine Curation products.
✅ Magnite Advances Agentic Vision as Major Media Owners, Buyers, and Technology Players Leverage Orchestration Layer — GlobeNewswire.
🤖 Magnite announced expanded omnichannel capabilities and third-party integrations for Magnite Orchestration, including connections across streaming, linear TV, audio, and display. The expansion could strengthen its position in emerging AI-driven advertising workflows.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 At/above 3yr high $70.48 (current $70.48) · ⏳ SMA200 $37.13 (current price $70.48 is above) · 💰 Market Cap $93.6B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 405% (>20%); Revenue growth 34% (>15%); Low LT D/E 0.82 (<1.0); PEG ratio 0.09 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (13.1%)
- 🔔 Strong above EMA50 (23.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 70 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Hewlett Packard Enterprise (HPE) Lands First $1.2 Billion ... — Yahoo Finance.
🤖 HPE received a $1.2 billion order from Vultr for its AMD Helios AI server racks, marking the first commercial deployment of the system. The order is an early revenue milestone for HPE’s integrated AI data-center platform.
✅ HPE stock closes at record high on growing networking orders, $1.2 billion AMD Helios order — Yahoo Finance.
🤖 The article reports strong demand for HPE networking and AI infrastructure, with fiscal 2026 networking orders expected to exceed prior guidance and a higher fiscal 2027 networking growth outlook. It also highlights the $1.2 billion Vultr order for HPE’s AMD Helios system.
✅ Hewlett Packard Enterprise stock had a week for the books — Yahoo Finance.
🤖 The article highlights the $1.2 billion Vultr order and an upbeat networking outlook. It also says analysts at several firms raised their price targets, reflecting optimism about HPE’s AI and networking prospects.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $63.79 is 9% below 3yr high $69.85 · ⏳ SMA200 $29.20 (current price $63.79 is above) · 💰 Market Cap $3.3B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (12.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (7.2%)
- 🔔 Strong above EMA50 (23.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ CareDx (NASDAQ:CDNA) Hits New 1-Year High — MarketBeat.
🤖 CareDx shares reached a new 52-week high, and the article notes BTIG’s price-target increase to $74 while maintaining a Buy rating. It also mentions institutional positions, which are routine ownership disclosures rather than a directional catalyst.
✅ CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? — Yahoo Finance.
🤖 The article attributes the share-price jump to BTIG raising its target to $74 from $60 while maintaining a Buy rating. It also cites 52% year-over-year second-quarter revenue growth, including 61% growth in testing services.
⚪️ CareDx (NASDAQ:CDNA) Shares Down 6.2% - Time to Sell? — MarketBeat.
🤖 The article reports a one-day share-price decline and recaps BTIG’s earlier price-target increase to $74 with a Buy rating. The price move itself is not a company-specific catalyst, and the analyst action was already reported separately.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Karat Packaging Inc. manufactures and distributes disposable foodservice products used by restaurants and other foodservice businesses. Its products include food and take-out containers, cups, lids, cutlery, straws, tableware, bags, and compostable packaging, along with related supplies and services.
- 🎯 Current $53.69 is 2% below 3yr high $54.68 · ⏳ SMA200 $32.86 (current price $53.69 is above) · 💰 Market Cap $1.1B
- KRT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (13.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 170% (>20%); ROE 30% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (12.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×3 ❌×1 ⚪️×1; showing 4 of 5).
✅ Karat Packaging (NASDAQ:KRT) Reaches New 1-Year High — MarketBeat.
🤖 The article reports KRT reached a new 52-week high and highlights second-quarter EPS of $1.48, well above the $0.47 consensus estimate, with revenue slightly above forecasts. The search result says it was published October 2, though it was later updated October 7, after the requested cutoff date.
✅ Zacks Industry Outlook Highlights Avery Dennison, AptarGroup and Karat Packaging — Zacks.
🤖 The outlook discusses Karat Packaging alongside other companies. Related search-result details cite record second-quarter sales, four new chain accounts, and 23.6% year-over-year online sales growth, supporting a positive view of business momentum.
❌ Karat Packaging: After A 100% Rally, Expectations Look Much Higher (Rating Downgrade) — Seeking Alpha.
🤖 The article downgrades KRT from Buy to Hold after a rally of more than 100%, citing elevated valuation and caution that second-quarter earnings were boosted by a one-time tariff refund. It also acknowledges operating growth, margin expansion, and supply-chain diversification.
⚪️ Karat Packaging Inc. (NASDAQ:KRT) Stock Has ... — MarketBeat.
🤖 The article reports a consensus Hold rating and a $47 average price target from six brokerages. It also notes Lake Street Capital reiterated its Buy rating and $60 target on September 14.
🍭 Bonus (B): 0/10 — Rubber & Plastics Products